Novartis AG Statistics
Total Valuation
Novartis AG has a market cap or net worth of BRL 1.54 trillion. The enterprise value is 1.67 trillion.
| Market Cap | 1.54T |
| Enterprise Value | 1.67T |
Important Dates
The last earnings date was Wednesday, February 4, 2026.
| Earnings Date | Feb 4, 2026 |
| Ex-Dividend Date | Mar 11, 2025 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -3.93% |
| Shares Change (QoQ) | -0.57% |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 37.29% |
| Float | 1.82B |
Valuation Ratios
The trailing PE ratio is 19.99 and the forward PE ratio is 17.21.
| PE Ratio | 19.99 |
| Forward PE | 17.21 |
| PS Ratio | 4.93 |
| PB Ratio | 6.01 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 15.89 |
| P/OCF Ratio | 14.60 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.19, with an EV/FCF ratio of 17.23.
| EV / Earnings | 21.68 |
| EV / Sales | 5.52 |
| EV / EBITDA | 13.19 |
| EV / EBIT | 16.48 |
| EV / FCF | 17.23 |
Financial Position
The company has a current ratio of 1.12, with a Debt / Equity ratio of 0.76.
| Current Ratio | 1.12 |
| Quick Ratio | 0.82 |
| Debt / Equity | 0.76 |
| Debt / EBITDA | 1.49 |
| Debt / FCF | 2.02 |
| Interest Coverage | 16.61 |
Financial Efficiency
Return on equity (ROE) is 30.81% and return on invested capital (ROIC) is 23.60%.
| Return on Equity (ROE) | 30.81% |
| Return on Assets (ROA) | 11.14% |
| Return on Invested Capital (ROIC) | 23.60% |
| Return on Capital Employed (ROCE) | 22.71% |
| Weighted Average Cost of Capital (WACC) | 6.27% |
| Revenue Per Employee | 4.15M |
| Profits Per Employee | 1.02M |
| Employee Count | 75,883 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 2.27 |
Taxes
In the past 12 months, Novartis AG has paid 13.14 billion in taxes.
| Income Tax | 13.14B |
| Effective Tax Rate | 14.59% |
Stock Price Statistics
The stock price has increased by +27.68% in the last 52 weeks. The beta is 0.45, so Novartis AG's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | +27.68% |
| 50-Day Moving Average | 74.58 |
| 200-Day Moving Average | 67.07 |
| Relative Strength Index (RSI) | 59.36 |
| Average Volume (20 Days) | 142 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novartis AG had revenue of BRL 312.16 billion and earned 77.02 billion in profits. Earnings per share was 39.38.
| Revenue | 312.16B |
| Gross Profit | 237.14B |
| Operating Income | 104.68B |
| Pretax Income | 90.07B |
| Net Income | 77.02B |
| EBITDA | 129.29B |
| EBIT | 104.68B |
| Earnings Per Share (EPS) | 39.38 |
Balance Sheet
The company has 63.52 billion in cash and 195.30 billion in debt, with a net cash position of -131.77 billion.
| Cash & Cash Equivalents | 63.52B |
| Total Debt | 195.30B |
| Net Cash | -131.77B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 256.39B |
| Book Value Per Share | 133.16 |
| Working Capital | 17.53B |
Cash Flow
In the last 12 months, operating cash flow was 105.45 billion and capital expenditures -8.53 billion, giving a free cash flow of 96.92 billion.
| Operating Cash Flow | 105.45B |
| Capital Expenditures | -8.53B |
| Free Cash Flow | 96.92B |
| FCF Per Share | n/a |
Margins
Gross margin is 75.97%, with operating and profit margins of 33.53% and 24.67%.
| Gross Margin | 75.97% |
| Operating Margin | 33.53% |
| Pretax Margin | 28.85% |
| Profit Margin | 24.67% |
| EBITDA Margin | 41.42% |
| EBIT Margin | 33.53% |
| FCF Margin | 31.05% |
Dividends & Yields
This stock pays an annual dividend of 1.42, which amounts to a dividend yield of 1.75%.
| Dividend Per Share | 1.42 |
| Dividend Yield | 1.75% |
| Dividend Growth (YoY) | -98.95% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 55.91% |
| Buyback Yield | 3.93% |
| Shareholder Yield | 5.69% |
| Earnings Yield | 5.00% |
| FCF Yield | 6.29% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Novartis AG has an Altman Z-Score of 3.81 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.81 |
| Piotroski F-Score | 7 |